<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586764</url>
  </required_header>
  <id_info>
    <org_study_id>HS22904</org_study_id>
    <nct_id>NCT04586764</nct_id>
  </id_info>
  <brief_title>ST Elevation Myocardial Infarction Hemodynamic OutComes: Role of Non-Invasive Cardiac System (SHOCk-NICaS) Study</brief_title>
  <acronym>SHOCk-NICaS</acronym>
  <official_title>ST Elevation Myocardial Infarction Hemodynamic OutComes: Role of Non-Invasive Cardiac System (SHOCk-NICaS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proposed novel solution for high-risk heart disease Overall in-hospital mortality among ST&#xD;
      elevation myocardial infarction (STEMI) patients is 3-4%, but &gt;50% patients experiencing&#xD;
      cardiogenic shock (CS) secondary to STEMI die in the hospital. Evidence suggests early&#xD;
      diagnosis and treatment of CS results in improved outcomes, albeit, there is no tool to&#xD;
      diagnose CS reliably in a timely fashion in STEMI patients through the continuous monitoring.&#xD;
      We hypothesize that bioimpedance-derived hemodynamic measures obtained using the Non-Invasive&#xD;
      Cardiac System (NICaS) can facilitate early detection of CS, predict outcomes, and&#xD;
      revolutionize the STEMI patient management. The objectives of SHOCk-NICaS study in STEMI&#xD;
      patients are to: a) identify the CS early, using NICaS derived cardiac index of ≤1.8L/min/m2&#xD;
      or ≤2.2L/min/m2 with the use of vasopressor and/or inotropes, and compare it with the&#xD;
      incidence of CS based upon lactate level ≥2mmol/L, and systolic blood pressure &lt;90mmHg; b):&#xD;
      determine the impact of primary percutaneous coronary intervention (PPCI), using NICaS&#xD;
      derived hemodynamic measures (stroke volume, cardiac index, cardiac power index, etc), by&#xD;
      comparing pre- and post-angioplasty; and c) identify outcome-associated hemodynamic markers.&#xD;
      A composite score of death during hospital stay, prolonged hospitalization due to heart&#xD;
      failure (&gt;72hrs), and use of inotropic or mechanical circulation support is a primary&#xD;
      outcome.&#xD;
&#xD;
      Methodology This is a multi-center, double-blind, prospective cohort study enrolling STEMI&#xD;
      patients aged ≥18years visiting at 4 cardiac centers (St Boniface, St. Michael's, McGill&#xD;
      University Hospital). Using validated NICaS protocol, hemodynamic parameters will be recorded&#xD;
      at baseline, during the PPCI procedure, and within 24-hour post PPCI without altering the&#xD;
      standard care. Statistical analysis: Baseline data will be reported as mean±SD or&#xD;
      median±interquartile range. The outcomes will be assessed using multivariable logistic&#xD;
      regression. We will analyze the impact of age, sex, gender, and ethnicity on hemodynamic&#xD;
      measures. The targeted 500 patients will ensure a margin of error of 5% at a 95% CI. So far&#xD;
      recruited 76 STEMI patients mark the study feasibility.&#xD;
&#xD;
      Significance This novel study in high-risk STEMI patients will provide a promising&#xD;
      cost-effective, rapid, and non-invasive tool to identify CS early; a prompt intervention may&#xD;
      curtail the high morbidity and mortality. The meticulously designed pragmatic study outcomes&#xD;
      may revolutionize STEMI patient management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged hospitalization due to heart failure (&gt; 96 hours)</measure>
    <time_frame>At 7 days</time_frame>
    <description>Documented pulmonary edema on x-ray chest, elevated BNP or initiation of diuretic therapy lasting longer than 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of inotropic - vasopressor therapy</measure>
    <time_frame>At 7 days</time_frame>
    <description>Use of norepinephrine, epinephrine, milrinone, dobutamine, or dopamine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of mechanical circulation support</measure>
    <time_frame>At 7 days</time_frame>
    <description>Intra aortic balloon pump, impella or extra-corporeal membrane oxygenation (ECMO) insertion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>At 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>At 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>At 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Killip classification</measure>
    <time_frame>At 24 hours</time_frame>
    <description>Killip class I - No signs of congestion Killip class II - Presence of S3 on clinical examination and/or basal rales on auscultation Class III - Acute pulmonary edema Class IV - Cardiogenic shock or hypotension (systolic blood pressure &lt; 90 mmHg) and evidence of peripheral vasoconstriction characterized by oliguria, cold extremities or sweating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial/ventricular arrhythmia</measure>
    <time_frame>At 30 days</time_frame>
    <description>Documented evidence of atrial - ventricular arrhythmia.&#xD;
Atrial fibrillation Atrial flutter Non-sustained ventricular tachycardia Sustained ventricular tachycardia Ventricular fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial/ventricular arrhythmia</measure>
    <time_frame>From 30 days to 1 year</time_frame>
    <description>Documented evidence of atrial - ventricular arrhythmia.&#xD;
Atrial fibrillation Atrial flutter Non-sustained ventricular tachycardia Sustained ventricular tachycardia Ventricular fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New diagnosis of heart failure</measure>
    <time_frame>At 30 days</time_frame>
    <description>Documented pulmonary edema on x-ray chest, elevated BNP or initiation of diuretic therapy lasting longer than 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New diagnosis of heart failure</measure>
    <time_frame>From 30 days to 1 year</time_frame>
    <description>Documented pulmonary edema on x-ray chest, elevated BNP or initiation of diuretic therapy lasting longer than 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantable Cardioverter Defibrillator (ICD) implantation</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Re-synchronization Therapy/Defibrillator (CRT-D) implantation</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>ST Elevation Myocardial Infarction (STEMI) Patients</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-Invasive Cardiac System</intervention_name>
    <description>Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with STEMI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥18 years, presenting with EKG confirmed diagnosis of STEMI&#xD;
&#xD;
          -  Able to understand, and consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to participate in the study&#xD;
&#xD;
          -  Patients with any life-threatening medical condition with an expected life span of ≤1&#xD;
             year (e.g., metastatic cancer, terminal COPD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashish H Shah, MD, MD-Res (UK),MRCP</last_name>
    <phone>204-237-2315</phone>
    <email>ashah5@sbgh.mb.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish H Shah, MD</last_name>
      <phone>204-237-2315</phone>
      <email>ashah5@sbgh.mb.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Ashish H Shah</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not decided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

